EWING SARCOMA

This study tests whether giving higher, more targeted doses of radiation over a shorter time can better control Ewing sarcoma tumors, especially larger ones. Researchers will personalize radiation doses based on tumor size and characteristics, aiming to reduce cancer recurrence a…

This is the first study in people testing a new drug called INBRX-109 for advanced cancers that have spread or come back after treatment. The main goals are to find a safe dose and see how the body handles the drug. Researchers will also look for early signs that it might help sh…

This study is testing if taking a drug called regorafenib for up to a year after finishing initial cancer treatment can help keep bone sarcomas from coming back. It will compare patients who take the drug to those who receive standard monitoring with no extra medication. The goal…

This early-stage study is testing the safety of a two-part treatment for advanced sarcomas that have stopped responding to standard therapies. Doctors take a patient's own immune cells, genetically modify them to recognize and attack cancer cells, and then infuse them back. These…

This study is testing a new type of immunotherapy for children and young adults (up to age 21) whose solid tumors have come back or haven't responded to standard treatments. Doctors take a patient's own immune cells (T cells), modify them in a lab to better target a protein calle…

This is the first time researchers are testing the experimental drug DXC008 in people. The study aims to find the safest dose and check for early signs that it might help control advanced prostate cancer and other solid tumors like Ewing sarcoma. It will involve about 110 adults …

This early-stage trial is testing the safety of a new combination treatment for children and young adults (up to age 21) whose bone or soft tissue cancers (sarcomas) have come back or haven't responded to standard treatments. The approach combines a short, intense course of radia…

This early-stage study is testing a new, flavored, oral version of a chemotherapy drug called irinotecan (named Orotecan®) in children and young adults whose solid tumors have come back. The main goals are to find a safe and effective dose and to see how the body processes the dr…

This study is testing a new, unapproved pill called silmitasertib, given alongside standard chemotherapy drugs. It aims to find a safe and effective dose for children and young adults under 30 whose solid tumors (like neuroblastoma or sarcoma) have come back or stopped responding…

This study is testing a drug called lurbinectedin in children and young adults whose Ewing sarcoma has come back or hasn't responded to other treatments. The first part aims to find a safe dose, and the second part will see how well the drug works to control the cancer. About 60 …

This early-stage study is testing a new drug called xaluritamig in children, teens, and adults with Ewing sarcoma that has returned or hasn't responded to standard chemotherapy. The main goals are to find a safe dose and understand how the body processes the drug. Researchers wil…

This study is testing a new oral drug, AMXT 1501, combined with an existing drug called DFMO, for children and young adults with aggressive cancers that have come back or didn't respond to standard treatments. The first part aims to find a safe dose, and the second part will comp…

This study is testing the safety of a new type of stem cell transplant for children whose cancers have come back or are very hard to treat. Doctors use a half-matched family donor and a special process to remove certain immune cells from the transplant, aiming to reduce complicat…

This study is testing a new drug called zilovertamab vedotin in children and young adults whose cancers have come back or haven't responded to standard treatments. It will enroll about 90 participants aged 1 year and older with specific blood cancers or solid tumors. The main goa…

This is a first-in-human safety study for a new, two-part cell therapy for children and young adults whose cancers have come back or haven't responded to standard treatments. Doctors will collect a patient's own immune cells, genetically modify them to better target the cancer, a…

This early-stage trial is testing a new oral medication called ST-01156 in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see how the body processes the drug. Researchers will also look for early s…

This study is testing a new type of stem cell transplant for children and young adults whose solid tumors have returned or not responded to standard treatments. Doctors are using a donor's stem cells that have been specially processed to remove certain immune cells, then combinin…

This study is testing a drug called lurbinectedin to see if it is safe and can control tumors in children and adults (age 10+) whose Ewing sarcoma or related cancers have come back after initial treatment. The drug is designed to target specific genetic changes that drive these t…

This early-stage study is testing the safety and initial effectiveness of combining two drugs, cabozantinib and high-dose ifosfamide, for children and adults whose bone or soft tissue sarcomas have returned or not responded to standard chemotherapy. The main goal is to find the s…

This trial is testing whether combining two existing cancer drugs—pembrolizumab and cabozantinib—can help control advanced sarcomas that have stopped responding to standard treatments. It will enroll about 119 adults with specific types of advanced sarcoma. The main goal is to se…

This study aims to improve the safety of fertility preservation for children with neuroblastoma or Ewing's sarcoma. Before cancer treatment, children can have ovarian or testicular tissue frozen to preserve future fertility, but there's a risk the tissue contains hidden cancer ce…

This study is testing whether a blood test can predict if two types of bone cancer (Ewing sarcoma and osteosarcoma) will come back after treatment. Researchers will collect blood samples from about 340 patients aged 1 to 50 years old to look for tiny pieces of tumor DNA. The goal…

This study aims to understand how well patients follow a personalized home exercise program after major leg surgery for bone cancer. Researchers will track 50 patients for six months to see how consistently they do their exercises and what factors might influence their commitment…